KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, Yan Ji, Andrew L Coveler, Andres Cervantes, Vaibhav Sahai, Anne Ploquin, Sandrine Hiret, Noelle K LoConte, Ivor J Percent, Charles D Lopez, Simon Pernot, Petr Kavan, Mary Mulcahy, Ryan Carr, Francis J Giles, Chris Seifarth, Andrey Ugolkov, Taylor Weiskittel, Gil Fine, Mark Jaros, Andrew P Mazar, Tanios S Bekaii-Saab

Nat Med 32(5) 1794-1804

PMID41981308
PMCIDPMC13190293
DOI10.1038/s41591-026-04327-4
发表日期2026-04-14
摘要

摘要

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is one of the leading causes of cancer-related mortality, but advances in therapeutic treatments remain limited. Elraglusib (9-ING-41), an inhibitor of GSK-3β, exhibits a multimodal mechanism of action based on antitumor activity in preclinical models of cancer, including pancreatic. The efficacy and safety of elraglusib with gemcitabine plus nab-paclitaxel (GnP) were assessed in patients with previously untreated mPDAC. In an open-label, international, multicenter, phase 2 study, patients were randomized 2:1 to weekly elraglusib/GnP or GnP alone. Primary endpoints were median overall survival (OS) and 1-year survival rate. The prespecified modified intention-to-treat population included 155 patients on elraglusib/GnP and 78 on GnP. As of the data cutoff of 27 April 2025, elraglusib/GnP improved median OS by 2.9 months and decreased the risk of death by 38% versus GnP (median OS 10.1 months versus 7.2 months, respectively (hazard ratio 0.62; 95% confidence interval 0.46 to 0.84; P = 0.01)). The 1-year survival rates were 44.1% versus 22.3%, respectively. The safety profile of elraglusib/GnP was manageable. The most common grade 3 or higher treatment-emergent adverse events (TEAEs) with elraglusib/GnP versus GnP alone were neutropenia (52.3% versus 30.8%), anemia (25.2% versus 29.5%) and fatigue (16.8% versus 5.1%). Explorative correlative analyses demonstrated that baseline circulating immune-related factors (that is, CXCL2 and TRAIL ligands) were associated with improved survival in the elraglusib/GnP arm. Treatment was accompanied by increases in intratumoral cytotoxic immune cell populations. Together, these findings support the clinical activity of elraglusib/GnP as first-line treatment in mPDAC and provide a biological context for the observed survival benefit. Based on the results of this phase 2 trial, a phase 3 trial is being planned. ClinicalTrials.gov registration: NCT03678883.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。